Showing results (51-60 of 67) with videos related to
Sort By:
Pageof 7
The Journal of Clinical Investigation|February 16, 2018
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockadeMehdi Touat, Tony Sourisseau, Nicolas Dorvault, et al.The New England Journal of Medicine|March 22, 2013
ERCC1 isoform expression and DNA repair in non-small-cell lung cancerLuc Friboulet, Ken André Olaussen, Jean-Pierre Pignon, et al.Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.European Urology Oncology|March 4, 2024
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate CancerLudovic Bigot, Jonathan Sabio, Loic Poiraudeau, et al.Molecular Cancer|October 4, 2024
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX developmentDamien Vasseur, Ludovic Bigot, Kristi Beshiri, et al.NPJ Precision Oncology|September 23, 2020
Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave RoussyGonzalo Recondo, Linda Mahjoubi, Aline Maillard, et al.Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.Pageof 7